AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Want to cut your energy bills? Here’s how five experts are doing it 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
RESEARCH TRIANGLE PARK, N.C., May 31, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Jefferies 2017 Global Healthcare Conference in New York on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
